<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01537653</url>
  </required_header>
  <id_info>
    <org_study_id>TDU12265</org_study_id>
    <secondary_id>U1111-1127-2719</secondary_id>
    <nct_id>NCT01537653</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of SAR231893 (REGN668) in Healthy Japanese Adult Male Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics of Ascending Single Subcutaneous Doses of SAR231893/REGN668 in Healthy Japanese Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary Objective:

      Assess the safety and tolerability of SAR231893 (REGN668) after ascending single subcutaneous
      (SC) doses in healthy Japanese adult male subjects

      Secondary Objectives:

      Assess the following parameters after ascending single SC doses in healthy Japanese adult
      male subjects

        -  The pharmacokinetics of SAR231893 (REGN668)

        -  The immunogenicity of SAR231893 (REGN668)

        -  Exploratory analyses of the pharmacodynamics of SAR231893 (REGN668)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total duration of the study period per subject is 11 weeks broken down as follows:

      Screening period = 2 to 21 days Treatment period = 57 days, including 1 treatment day
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with standard safety assessments (adverse events, physical examinations, 12 lead ECGs, vital signs and laboratory tests)</measure>
    <time_frame>Up to 57 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Serum concentrations of SAR231893 (REGN668) over time</measure>
    <time_frame>Up to 57 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Serum total Immunoglobulin E (IgE) and Thymus and activation regulated chemokine (TARC) over time</measure>
    <time_frame>Up to 57 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>SAR231893 (REGN668), Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Level 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAR231893 (REGN668), Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Level 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAR231893 (REGN668), Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Level 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAR231893 (REGN668), Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Level 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR231893 (REGN668)</intervention_name>
    <description>Pharmaceutical form:Solution in a vial Route of administration: Subcutaneous injection</description>
    <arm_group_label>SAR231893 (REGN668), Dose Level 4</arm_group_label>
    <arm_group_label>SAR231893 (REGN668), Dose Level 1</arm_group_label>
    <arm_group_label>SAR231893 (REGN668), Dose Level 2</arm_group_label>
    <arm_group_label>SAR231893 (REGN668), Dose Level 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Pharmaceutical form:Solution in a vial Route of administration: Subcutaneous injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Japanese adult male subjects, between 20 and 45 years of age, inclusive.

          -  Body weight between 50.0 and 95.0 kg, inclusive, body mass index between 18.0 and 28.0
             kg/m2, inclusive.

          -  Certified as healthy by a comprehensive clinical assessment.

          -  Having given written informed consent prior to undertaking any study-related
             procedure.

        Exclusion criteria:

          -  Any history or presence of clinically relevant cardiovascular, pulmonary,
             gastrointestinal, hepatic, renal, metabolic, hematological, neurological,
             osteomuscular, articular, psychiatric, systemic, ocular, or infectious disease, or
             signs of acute illness.

          -  Any subject who cannot prohibit intensive physical activity throughout the study
             duration.

          -  Positive result on any of the following tests: hepatitis B surface (HBs Ag) antigen,
             anti-hepatitis B core antibodies (anti-HBc Ab), anti-hepatitis C virus (anti-HCV)
             antibodies, human immunodeficiency virus (HIV) antigen and antibodies.

          -  Positive result on urine drug screen (amphetamines/methamphetamines, barbiturates,
             benzodiazepines, cannabinoids, cocaine, opiates).

          -  Serum alcohol level over the upper limit of normal range (ULN).

          -  Previous exposure to any therapeutic or investigational biological agent.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 392001</name>
      <address>
        <city>Toshima-Ku</city>
        <zip>171-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2012</study_first_submitted>
  <study_first_submitted_qc>February 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2012</study_first_posted>
  <last_update_submitted>December 5, 2013</last_update_submitted>
  <last_update_submitted_qc>December 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

